Voyager Therapeutics' VY1706 Receives FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Voyager Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application for VY1706, the company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease. The IND clearance enables initiation of a clinical trial of VY1706 in adults with early AD; dosing is expected to begin in the second half of the year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VYGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VYGR
Wall Street analysts forecast VYGR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.620
Low
8.00
Averages
13.20
High
25.00
Current: 3.620
Low
8.00
Averages
13.20
High
25.00
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Clears IND for Voyager's VY1706 Alzheimer's Gene Therapy
- Clinical Trial Launch: Voyager Therapeutics announced that the FDA has cleared the Investigational New Drug application for its Alzheimer's gene therapy VY1706, with plans to initiate a multi-site, open-label dose-escalation clinical trial in the second half of the year, recruiting up to 18 early-stage patients.
- Drug Mechanism: VY1706 utilizes a vectorized siRNA core targeting MAPT mRNA to reduce levels of both intracellular and extracellular tau protein, with preclinical studies demonstrating a favorable pharmacology and safety profile, potentially offering a new treatment option for Alzheimer's patients.
- Trial Objectives: The primary endpoint of the clinical trial is to evaluate the safety and tolerability of VY1706, while secondary endpoints will assess its effects on tau biology, including changes in cerebrospinal fluid biomarkers of tau and tau pathology measured by PET imaging.
- Stock Price Fluctuation: VYGR's stock has traded between $2.83 and $5.55 over the past year, closing at $3.79 on Monday, down 2.07% from the previous trading day, reflecting market caution regarding the progress of the new drug development.
See More
Voyager Therapeutics Receives FDA Approval for Alzheimer's Clinical Trial
- Clinical Trial Launch: Voyager Therapeutics announced that its gene therapy VY1706 for Alzheimer's disease has received FDA IND approval, with dosing expected to begin in H2 2026 for early-stage Alzheimer's patients, marking a significant step towards potential new treatment options for this debilitating condition.
- Innovative Mechanism: VY1706 employs an IV delivery method utilizing a novel AAV capsid to target tau proteins in the brain, demonstrating up to 75% reduction in tau levels across various animal models, indicating substantial therapeutic potential in addressing Alzheimer's pathology.
- Favorable Safety Profile: Three-month GLP toxicology studies in non-human primates showed that VY1706 has a favorable tolerability profile with no adverse clinical or histopathological findings, supporting its safety for clinical application and enhancing investor confidence.
- Strong Market Demand: With approximately 7.2 million people affected by Alzheimer's in the U.S. and an estimated 32 million globally, the growing need for effective treatment options underscores the strategic importance of VY1706's development, which could significantly improve patient quality of life and alleviate healthcare costs.
See More
VY1706 IND Application on Track for Q2 2026 with Promising Data
- Clinical Application Progress: Voyager Therapeutics is on track to complete the IND application for VY1706 by Q2 2026, supporting the first-in-human trial for Alzheimer's patients in H2 2026, marking a significant milestone in the treatment of neurological diseases.
- Safety Data: At the ASGCT annual meeting, GLP toxicology data for VY1706 showed no adverse clinical or histopathological findings at the highest tested dose (5E13 vg/kg), with tau protein reductions of up to 64% in non-human primates, indicating good tolerability and potential therapeutic effects.
- Drug Delivery Innovation: VY1706 demonstrated broad central nervous system distribution via a single IV dose, achieving dose-dependent reductions of MAPT mRNA and tau protein by 51-75% and 48-64%, respectively, paving the way for new possibilities in gene therapy for Alzheimer's disease.
- Platform Advantages: Voyager's TRACER™ platform excels in developing novel AAV capsids that effectively evade human neutralizing antibodies while enhancing muscle targeting capabilities, which is expected to expand the eligible patient population and further drive clinical applications of gene therapies.
See More
Voyager Therapeutics Q1 Financial Results Analysis
- Revenue and Loss: In Q1 2026, Voyager Therapeutics reported revenue of $2.6 million and a net loss of $27.9 million, indicating significant challenges in profitability despite a slight increase in revenue.
- R&D Expense Reduction: R&D expenses for Q1 were $24.6 million, down from $31.5 million in Q1 2025, primarily due to cost-cutting and efficiency initiatives, although increased costs related to the tau silencing gene therapy program suggest strategic shifts in R&D focus.
- Decrease in Administrative Costs: General and administrative expenses decreased to $8.3 million in Q1 2026 from $9.6 million in the previous year, reflecting effective cost control measures taken by the company to address ongoing financial pressures.
- Cash Flow Position: As of March 31, 2026, Voyager had $171.7 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet operating and capital expenditure needs through 2028, indicating a degree of financial stability.
See More
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
- Orphan Drug Status: The FDA has granted orphan drug designation to Neurocrine Biosciences' NBIB-223 (frataxin), which allows for up to seven years of market exclusivity post-approval, significantly enhancing its commercial potential.
- Tax Incentives: With orphan drug status, NBIB-223 will benefit from tax credits for clinical trial expenses, reducing R&D costs and thereby strengthening Neurocrine's competitive position in the Friedreich ataxia treatment landscape.
- Gene Therapy Innovation: NBIB-223 is a gene therapy that employs Voyager Therapeutics' modified AAV capsid to deliver the frataxin gene throughout the body, showcasing Neurocrine's commitment to cutting-edge medical technology and innovation.
- Market Competition: The only approved treatment for Friedreich ataxia is Biogen's Skyclarys (omaveloxolone), and the introduction of NBIB-223 will provide patients with more options while potentially challenging Biogen's market share.
See More
VY1706 Gene Therapy Shows Safety in Alzheimer's Study
- Preclinical Data Showcase: VY1706 demonstrates compelling pharmacology and safety in a three-month GLP toxicology study in non-human primates, indicating its potential as a treatment for Alzheimer's disease, with clinical trials expected to commence in the second half of 2026, potentially offering new therapeutic options for patients.
- Technological Innovation: The novel AAV capsids developed through Voyager's TRACER platform effectively penetrate the blood-brain barrier and achieve widespread drug expression, enhancing treatment capabilities for Alzheimer's while opening new avenues for other neurological disorders.
- Immune Evasion Strategy: The application of new technologies allows VY1706 to expand the eligible patient population while minimizing immune responses, which not only improves treatment efficacy but also potentially reduces side effects, increasing patient acceptance.
- Future Development Plans: Voyager aims to submit an IND application in Q2 2026, marking a significant advancement in its Alzheimer's program, which is expected to create new market opportunities and bolster investor confidence.
See More
FDA Clears IND for Voyager's VY1706 Alzheimer's Gene Therapy
- Clinical Trial Launch: Voyager Therapeutics announced that the FDA has cleared the Investigational New Drug application for its Alzheimer's gene therapy VY1706, with plans to initiate a multi-site, open-label dose-escalation clinical trial in the second half of the year, recruiting up to 18 early-stage patients.
- Drug Mechanism: VY1706 utilizes a vectorized siRNA core targeting MAPT mRNA to reduce levels of both intracellular and extracellular tau protein, with preclinical studies demonstrating a favorable pharmacology and safety profile, potentially offering a new treatment option for Alzheimer's patients.
- Trial Objectives: The primary endpoint of the clinical trial is to evaluate the safety and tolerability of VY1706, while secondary endpoints will assess its effects on tau biology, including changes in cerebrospinal fluid biomarkers of tau and tau pathology measured by PET imaging.
- Stock Price Fluctuation: VYGR's stock has traded between $2.83 and $5.55 over the past year, closing at $3.79 on Monday, down 2.07% from the previous trading day, reflecting market caution regarding the progress of the new drug development.
See More
Voyager Therapeutics Receives FDA Approval for Alzheimer's Clinical Trial
- Clinical Trial Launch: Voyager Therapeutics announced that its gene therapy VY1706 for Alzheimer's disease has received FDA IND approval, with dosing expected to begin in H2 2026 for early-stage Alzheimer's patients, marking a significant step towards potential new treatment options for this debilitating condition.
- Innovative Mechanism: VY1706 employs an IV delivery method utilizing a novel AAV capsid to target tau proteins in the brain, demonstrating up to 75% reduction in tau levels across various animal models, indicating substantial therapeutic potential in addressing Alzheimer's pathology.
- Favorable Safety Profile: Three-month GLP toxicology studies in non-human primates showed that VY1706 has a favorable tolerability profile with no adverse clinical or histopathological findings, supporting its safety for clinical application and enhancing investor confidence.
- Strong Market Demand: With approximately 7.2 million people affected by Alzheimer's in the U.S. and an estimated 32 million globally, the growing need for effective treatment options underscores the strategic importance of VY1706's development, which could significantly improve patient quality of life and alleviate healthcare costs.
See More
VY1706 IND Application on Track for Q2 2026 with Promising Data
- Clinical Application Progress: Voyager Therapeutics is on track to complete the IND application for VY1706 by Q2 2026, supporting the first-in-human trial for Alzheimer's patients in H2 2026, marking a significant milestone in the treatment of neurological diseases.
- Safety Data: At the ASGCT annual meeting, GLP toxicology data for VY1706 showed no adverse clinical or histopathological findings at the highest tested dose (5E13 vg/kg), with tau protein reductions of up to 64% in non-human primates, indicating good tolerability and potential therapeutic effects.
- Drug Delivery Innovation: VY1706 demonstrated broad central nervous system distribution via a single IV dose, achieving dose-dependent reductions of MAPT mRNA and tau protein by 51-75% and 48-64%, respectively, paving the way for new possibilities in gene therapy for Alzheimer's disease.
- Platform Advantages: Voyager's TRACER™ platform excels in developing novel AAV capsids that effectively evade human neutralizing antibodies while enhancing muscle targeting capabilities, which is expected to expand the eligible patient population and further drive clinical applications of gene therapies.
See More
Voyager Therapeutics Q1 Financial Results Analysis
- Revenue and Loss: In Q1 2026, Voyager Therapeutics reported revenue of $2.6 million and a net loss of $27.9 million, indicating significant challenges in profitability despite a slight increase in revenue.
- R&D Expense Reduction: R&D expenses for Q1 were $24.6 million, down from $31.5 million in Q1 2025, primarily due to cost-cutting and efficiency initiatives, although increased costs related to the tau silencing gene therapy program suggest strategic shifts in R&D focus.
- Decrease in Administrative Costs: General and administrative expenses decreased to $8.3 million in Q1 2026 from $9.6 million in the previous year, reflecting effective cost control measures taken by the company to address ongoing financial pressures.
- Cash Flow Position: As of March 31, 2026, Voyager had $171.7 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet operating and capital expenditure needs through 2028, indicating a degree of financial stability.
See More
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
- Orphan Drug Status: The FDA has granted orphan drug designation to Neurocrine Biosciences' NBIB-223 (frataxin), which allows for up to seven years of market exclusivity post-approval, significantly enhancing its commercial potential.
- Tax Incentives: With orphan drug status, NBIB-223 will benefit from tax credits for clinical trial expenses, reducing R&D costs and thereby strengthening Neurocrine's competitive position in the Friedreich ataxia treatment landscape.
- Gene Therapy Innovation: NBIB-223 is a gene therapy that employs Voyager Therapeutics' modified AAV capsid to deliver the frataxin gene throughout the body, showcasing Neurocrine's commitment to cutting-edge medical technology and innovation.
- Market Competition: The only approved treatment for Friedreich ataxia is Biogen's Skyclarys (omaveloxolone), and the introduction of NBIB-223 will provide patients with more options while potentially challenging Biogen's market share.
See More
VY1706 Gene Therapy Shows Safety in Alzheimer's Study
- Preclinical Data Showcase: VY1706 demonstrates compelling pharmacology and safety in a three-month GLP toxicology study in non-human primates, indicating its potential as a treatment for Alzheimer's disease, with clinical trials expected to commence in the second half of 2026, potentially offering new therapeutic options for patients.
- Technological Innovation: The novel AAV capsids developed through Voyager's TRACER platform effectively penetrate the blood-brain barrier and achieve widespread drug expression, enhancing treatment capabilities for Alzheimer's while opening new avenues for other neurological disorders.
- Immune Evasion Strategy: The application of new technologies allows VY1706 to expand the eligible patient population while minimizing immune responses, which not only improves treatment efficacy but also potentially reduces side effects, increasing patient acceptance.
- Future Development Plans: Voyager aims to submit an IND application in Q2 2026, marking a significant advancement in its Alzheimer's program, which is expected to create new market opportunities and bolster investor confidence.
See More
